10,11-dihydro-5H-dibenzocyclohepten-5,10-imine | 50537-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 10,11-dihydro-5H-dibenzocyclohepten-5,10-imine
• 英文别名: 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine；dl-10,11-Dihydro-5,10-imino-(5H)-dibenzo(a,d)cycloheptene；16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
• CAS: 50537-17-2
• 化学式: C₁₅H₁₃N
• 分子量: 207.275
• InChiKey: SAWOLAINNGNEPL-UHFFFAOYSA-N

物化性质

• 熔点：
  111.5-114.0 °C
• 沸点：
  325.2±11.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  10,11-dihydro-5H-dibenzocyclohepten-5,10-imine 在 六甲基磷酰三胺 、 ammonium sulfate 、 硫酸 、 氰化钠 、 氨 、 仲丁基锂 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 反应 196.5h， 生成 5-氨基羰基-10,11-二氢-5H-二苯并(a,d)环庚烯-5,10-亚胺
  参考文献：
  名称：

  Synthesis and structure-activity relationship of C5-substituted analogs of (.+-.)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine [(.+-.)-desmethyl-MK801]: ligands for the NMDA receptor-coupled phencyclidine binding site

  摘要：

  A series of eight C5-substituted analogues of (+-)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (1) have been prepared by the directed lithiation-alkylation (and acylation) of its (+-)-N-tert-butylformamidinyl derivative 2 followed by formamidine solvolysis. An additional 10 analogues were prepared by elaboration of the C5-ethyl ester derivative. Analogues possessing large (e.g. propyl and larger) lipophilic substituents displace [3H]-1-(1-thienylcyclohexyl)piperidine [( 3H]TCP) from the high-affinity phencyclidine (PCP) binding site in rat brain homogenates only at high concentrations (Ki greater than 1000 nM); however, the presence of a polar amino functionality (e.g. 2-aminoethyl) offsets this effect (Ki = 20 nM). Thus, the boundary condition for lipophilic substituents larger than ethyl appears to be polar in nature. Interaction of the 11 relatively small (MR less than 14) C5-substituted analogues of 1 with the high-affinity PCP binding site associated with the N-methyl-D-aspartate (NMDA) receptor is best described by the equation log (1/Ki) = -5.83F + 0.64 pi + 7.41 (r = 0.90).

  DOI：

  10.1021/jm00165a029
• 作为产物：
  描述：

  5H-二苯并[Α,D]环庚三烯-5-醇 在 palladium on activated charcoal 盐酸 、 二氯乙酸 、 正丁基锂 、 盐酸羟胺 、 氢气 、 sodium acetate 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 溶剂黄146 、 二甲基亚砜 、 异丙醇 为溶剂， 25.0~60.0 ℃ 、275.79 kPa 条件下， 反应 4.5h， 生成 10,11-dihydro-5H-dibenzocyclohepten-5,10-imine
  参考文献：
  名称：

  .alpha.-Effect nucleophiles: a novel and convenient method for the synthesis of dibenzo[a,d]cycloheptenimines

  摘要：

  DOI：

  10.1021/jo00243a031

文献信息

• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：——

  公开号：US20010051633A1

  公开（公告）日：2001-12-13

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑，精神病，惊厥，氨基糖苷类抗生素引起的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，巨细胞病毒性视网膜炎，尿失禁，阿片类耐受或戒断，并诱导麻醉，以及增强认知能力。
• Imino-bridged benzocycloheptapyridines, process for their preparation and pharmaceutical composition thereof
  申请人：Merck & Co., Inc.

  公开号：EP0002512A1

  公开（公告）日：1979-06-27

  Compounds of the formula wherein R, and R2 are hydrogen, alkyl, alkenyl, phenylalkyl, cycloalkyl or cycloalkylalkyl, R is R1, phenyl or dialkylaminoalkyl, and R3 is hydrogen, halogen, alkoxy, trifluoromethylthio, cyano or carboxy, are useful as anti-auxiety agents, as muscle relaxants and in the treatment of extra- . pyramidal disorders such as in Parkinson's disease.

  式中的化合物 其中 R 和 R2 是氢、烷基、烯基、苯基烷基、环烷基或环烷基烷基，R 是 R1、苯基或二烷基氨基烷基，R3 是氢、卤素、烷氧基、三氟甲硫基、氰基或羧基，可用作抗焦虑剂、肌肉松弛剂和治疗锥体外系疾病，如帕金森病。
• 9,10-Dihydro-4H-benzo(4,5)cyclohepta(1,2-b)thiophen-4,9 imines, process for their preparation and pharmaceutical compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0011206A1

  公开（公告）日：1980-05-28

  9,10-Dihydro-4H-benzo(4,5) cyclohepta(1,2-b) thiophen-4,5-imines of the formula wherein R is hydrogen, alkyl, alkenyl, phenyl (or substituted phenyl) alkyl, cycloalkyl, cycloalkylalkyl, dialkylaminoalkyl, R2 is hydrogen, alkyl, alkenyl, phenylalkyl, cycloalkylalkyl, dialkylaminoalkyl and R3 and R. are hydrogen, halogen, alkoxy, trifluoromethylthio, cyano, carboxy or hydroxy, are useful as antianxiety agents, as muscle relaxants and in the treatment of extrapyramidal disorders such as in Parkinson's disease.

  9,10-二氢-4H-苯并(4,5)环庚烷(1,2-b)噻吩-4,5-亚胺，其式为 其中 R 是氢、烷基、烯基、苯基（或取代苯基）烷基、环烷基、环烷基烷基、二烷基氨基烷基，R2 是氢、烷基、烯基、苯基烷基、环烷基烷基、二烷基氨基烷基，R3 和 R. 是氢、卤素、烷氧基、三氟甲硫基、氰基、羧基或羟基，可用作抗焦虑剂、肌肉松弛剂和治疗锥体外系疾病，如帕金森病。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。